clinical trial

Federal health authorities recommend a pneumococcal vaccine for children 2 and under, adults over 64, and people of all ages with certain medical conditions.

Children ages 12 to 17 are needed in a trial for the Novovax vaccine, which uses a protein therapeutic to attack the coronavirus, unlike the current vaccines currently in use.

Elderly people and people from minority communities who have been hardest hit by COVID-19 are encouraged to apply to be part of the study.

Kim Hudak was a young mother who was done having children when she volunteered for a clinical trial to an experimental birth control implant designed to…

In a lab the size of a basketball court, Moffitt scientist Kieran Smalley and his team study human genes and proteins involved in different kinds of…